<DOC>
	<DOCNO>NCT01327313</DOCNO>
	<brief_summary>The primary objective assess safety tolerability single repeat dos EMD525797 , characterize Pharmacokinetics ( PK ) . The secondary objective investigate immunogenicity Progressive disease ( PD ) , assess anti-tumor activity EMD525797 .</brief_summary>
	<brief_title>A Study EMD525797 Solid Tumor Patients Japan</brief_title>
	<detailed_description />
	<criteria>Age great equal ( &gt; = ) 20 year Histologically cytologically proven advanced metastatic solid tumor Evidence progressive disease standard chemotherapy standard chemotherapy Confirmation availability formalinfixed paraffinembedded ( FFPE ) tumor block ( ) tissue section Presence least one measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) Version 1.0 complete tumor assessment perform within 30 day prior first EMD525797 administration Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Estimated life expectancy least 3 month Absolute Neutrophil Count ( ANC ) &gt; = 1.5 x 10^9 per liter ( /Liter ) Platelets &gt; = 100 x 10^9/Liter Haemoglobin &gt; = 9.0 gram per deciliter ( g/dL ) ( without transfusion ) Total bilirubin less equal ( &lt; = ) 1.5 x upper limit normal ( ULN ) Aspartate transaminase ( AST ) , alanine transaminase ( ALT ) less equal ( &lt; = ) 3 x ULN In subject hepatic metastasis , total bilirubin &lt; = 3 x ULN , AST ALT &lt; = 5 x ULN Prothrombin time ( PT ) , prothrombin time/international normalize ratio ( PT/INR ) , activate partial thromboplastin time ( APTT ) within normal limit Creatinine clearance &gt; = 50 milliliter per minute ( mL/min ) Other protocol define inclusion criterion could also apply Previous treatment antiintegrin therapy Radiotherapy bone lesion , systemic surgery , orthopedic surgery ( within 4 week prior treatment EMD525797 ) , clinically significant unhealed wound , unrecovered bone fracture Chronic dose oral steroid , define &gt; = 10 milligram prednisone equivalent per day Confirmed clinically suspect brain leptomeningeal metastasis Known hypersensitivity EMD525797 excipients History allergic reaction monoclonal antibody therapy Antibody treatment within past 8 week chemotherapy within 4 week prior treatment EMD525797 Uncontrolled diabetes Uncontrolled hypertension define systolic blood pressure &gt; = 160 millimeter mercury ( mmHg ) and/or diastolic blood pressure &gt; = 100 millimeter mercury ( mmHg ) rest condition Autoimmune diseases Current history chronic daily acetylsalicylic acid ( ASS ) therapy ( ASS dose &lt; =100 mg permit ) Bleeding disorder ; History thromboembolic event ( history superficial thrombophlebitis exclusion Anticoagulants within past 10 day prior first treatment treatment period Severe peripheral vascular disease ulceration Unstable angina pectoris , myocardial infarction severe heart disease within past 6 month treatment EMD 525797 Clinical significant abnormal ECG screening Dementia , alter mental status , psychiatric condition would prohibit understanding rendering informed consent Known HIV infection , active chronic carrier hepatitis B virus ( HBV antigen positive HBV DNA positive ) hepatitis C virus ( HCV antibody positive ) Other protocol define exclusion criterion could also apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>alpha v integrin</keyword>
	<keyword>antibody</keyword>
	<keyword>solid tumor</keyword>
	<keyword>Japanese</keyword>
	<keyword>EMD525797</keyword>
</DOC>